Introduction
Clostridium difficile-associated disease has emerged as a major nosocomial infection in North American and European hospitals, with a rising incidence, increasing severity and an increasing rate of failure to conventional therapy. 1 -4 Vancomycin was the first drug shown to provide effective treatment for this condition 5 and, at least in the USA, remains the only one approved for this purpose by the Food and Drug Administration. 6 Early studies, however, appeared to show metronidazole to be equally effective. 6 -8 Initially driven by the prohibitive cost of oral vancomycin, and subsequently by fear of selecting vancomycin-resistant bacteria in hospitals, health-care providers have tended to prescribe metronidazole, which is now recommended as first-line therapy for this condition, 9, 10 even though the response to vancomycin is somewhat more rapid. 11 We 4 and others 3, 12 have recently documented a substantial rate of failure with this therapy. When treatment with metronidazole fails, most infectious disease specialists 13, 14 recommend oral vancomycin, but continuing concerns over the high cost and the emergence of vancomycin-resistant bacteria, reinforced by federal guidelines discouraging excessive use of this medication, 15 have motivated the search for alternative therapy.
Nitazoxanide, a nitrothiazolide, successfully treats infestation by intestinal parasites and is approved in the USA and UK to treat cryptosporidiosis and giardiasis. 16, 17 This drug acts by blocking anaerobic metabolism. In vitro, low concentrations of nitazoxanide or its breakdown product, tizoxanide, inhibit C. difficile.
18 Two-thirds of an administered dose is excreted in the faeces. 19 In a prospective, double-blind study, we 20 recently found that nitazoxanide is at least as effective as metronidazole in treating patients with moderately severe or severe C. difficile colitis. Taken together, these factors motivated us to study nitazoxanide in patients with C. difficile colitis who had failed conventional therapy with metronidazole. Interestingly, Bartlett 21 also suggested this possibility in a recent editorial on the subject.
Patients and methods

Study site
This study was carried out at the Michael E. DeBakey Veterans Affairs Medical Center, Houston. Patients in this system generally rely exclusively on this centre for their medical care. Medical and laboratory records are fully automated, and every encounter between a patient and the medical system is recorded electronically. Thus, follow-up data tend to be remarkably complete. During the time of this study, the therapy approved in our hospital for treating C. difficile colitis was metronidazole. For reasons summarized above, vancomycin was used infrequently, and an order to do so required approval by a member of the Infectious Disease Section.
Patients
Patients who had clearly failed conventional treatment for C. difficile colitis were asked to participate in an IRB-approved open-label study of nitazoxanide (Institutional Review Board, Baylor College of Medicine, Protocol H-15601). Therapeutic failure was defined as either: (i) the absence of a response to metronidazole and/or oral vancomycin therapy, defined as persistence of fever, diarrhoea (at least three loose or watery stools per day), abdominal pain and/or otherwise unexplained leucocytosis and a positive EIA for C. difficile toxin after 14 days of oral treatment with a total dosage 1.5 g of oral metronidazole or 500 mg of oral vancomycin daily; or (ii) on at least two occasions, an initial response to metronidazole or vancomycin, as defined by resolution of the above-named symptoms, followed within 30 days by recurrence. Because metronidazole may be effective in treating an initial recurrence of disease, 22, 23 in order to be included in this study, patients needed to have at least two bouts of recurrent symptoms and signs of colitis after a full course of treatment. Symptoms were present for 4 days before the diagnosis of recurrent disease was made. Nitazoxanide, 500 mg, was given twice daily, for 10 days. Initially, informed consent was sought in accordance with IRB guidelines. After the first 22 patients were treated, the results of the double-blind study comparing metronidazole to nitazoxanide were revealed, 20 and nitazoxanide was placed on the hospital formulary, requiring approval for its use by one of the investigators (DMM or RJH). Thereafter, 13 additional patients who failed conventional therapy were treated with nitazoxanide but without informed consent being required. All patients were followed closely throughout their treatment and thereafter for 60 days in order to determine whether there was a recurrence. A separate IRB-approved protocol (Baylor IRB H-16175) authorized a review of all medical records after treatment had been completed. Data presented in this paper are from 35 consecutive patients who met the above criteria and were treated with nitazoxanide; results from all patients are included.
Response to treatment
Patients were seen regularly by an investigator after treatment with nitazoxanide was begun. Interviews with patients, family members and nurses were used to determine the number and quality of stools, and the persistence of fever, abdominal discomfort and/or leucocytosis was noted. Failure of therapy was defined by the persistence of at least three loose or watery stools per 24 h, along with fever, leucocytosis, abdominal pain and/or urgency. A response to treatment was defined as the absence of symptoms of disease as defined above. After the study was over, complete electronic medical records were reviewed for 60 days to verify all recorded information and to determine whether there had been a recurrence or possible recurrence of C. difficile colitis. Patients were said to have undergone an apparent cure when, after a response, there was no recurrence of symptoms or signs of colitis during the ensuing 60 days. An initial response to nitazoxanide followed by a return of these symptoms and signs together with a positive faecal C. difficile toxin assay was termed a recurrence.
Microbiology
C. difficile toxin was detected by EIA (Premier TM Toxins A&B, Meridian Bioscience, Cincinnati, OH, USA). Faecal samples from some patients were submitted in anaerobic transport containers to Microbiology Specialists Incorporated (Houston, TX, USA) for anaerobic culture. Definitive identification of C. difficile was by distinctive isoacid production on gas liquid chromatography. Susceptibilities to vancomycin, metronidazole, nitazoxanide and tizoxanide were studied by agar dilution. Isolates were sent to the Centers for Disease Control and Prevention (Atlanta, GA, USA) where Dr Charles E. Kilgore, Ms Angela Thompson and Dr L. Clifford McDonald graciously performed PFGE, toxinotyping and detection of binary toxin production. 24 
Results
Demographics
Thirty-five consecutive patients who were treated with nitazoxanide after failing conventional therapy for C. difficile colitis are included in this report. Thirty-three were male and two were female, consistent with gender distribution at our hospital. The mean age was 67.5 years (range 49-86). In 28 patients, symptoms and signs of C. difficile colitis had persisted without response despite treatment with metronidazole for 14 days; seven had at least two recurrences after appropriate treatment (Figure 1 ). Those with persistent disease had been treated with metronidazole for 17-45 days (mean ¼ 22.4 days, median ¼ 21 days); two also received .14 days of vancomycin. Patients with recurrent disease had received at least two (mean ¼ 2.6, median ¼ 2) courses of treatment with metronidazole; two of these had also received at least one course of oral vancomycin.
Patients in this series were very ill, each having numerous, serious co-morbid conditions; these are summarized in Table 1 . Seven patients (20%) died during treatment or in the ensuing 30 days, giving further insight into the severity of illness.
Prior antibiotic use
Thirty-three (94%) patients had received antibiotics for a mean of 43.2 (range 8-131) antibiotic days, defined as sum of the number of days for each individual antibiotic, in the 8 weeks preceding the initial bout of C. difficile colitis. 25 Two patients who had not taken antibiotics were undergoing radiation therapy for colon cancer (one case) or chemotherapy for lymphoma (one case). In all but two cases, there was at least one time period when the patient was receiving no antibiotics yet had persistent findings of C. difficile colitis.
Response to nitazoxanide
There appeared to be no differences in response to nitazoxanide among patients who had failed metronidazole and those who had recurrence of disease after initial responses. Thus, for ease of presentation, results are merged for the two groups, although Figure 2 shows actual outcomes for all 35 patients. Twenty-six of the 35 (74%) patients had a rapid resolution of symptoms and signs of colitis after nitazoxanide therapy was begun (Figure 2) , including 20 of the 28 (71%) who had persisting disease despite metronidazole and 6 of the 7 (86%) who had recurrent disease (difference not significant, P ¼ 0.65, Fisher's exact test). Diarrhoea stopped within a mean of 2.6 days (range 1 -4). Febrile patients defervesced and leucocytosis, when attributable to the colitis, resolved within 4 days. Sixty days after treatment, 19 of these 26 (73%; 54% of the original 35 patients) remained free of symptoms or signs of colitis and were regarded as apparent cures.
Seven of the 26 patients who initially responded to nitazoxanide (27%; 20% of the original 35 patients) had recurrent C. difficile colitis within a mean of 12.1 (range 7 -24) days after the completion of therapy (Figure 2 ). After the initial course of therapy with nitazoxanide, treatment of any subsequent failure or recurrence was selected by the primary care providers. Of these seven patients with recurrent disease, one was re-treated with nitazoxanide and responded. Four were treated with metronidazole, of whom two were cured and two failed to respond (one of these received vancomycin and metronidazole together without response). Two were treated with vancomycin of whom one initially responded but died before completion of therapy and one failed, eventually dying with persistent C. difficile colitis.
Nine of the 35 (26%) patients failed nitazoxanide (Figure 2 ). One died in the first week of therapy. Two were re-treated with metronidazole but failed to respond. One each of these was subsequently treated successfully with an additional course of nitazoxanide or vancomycin (responding only to a second course of this drug). Three were re-treated with nitazoxanide; one was cured, one was eventually cured after two additional courses of nitazoxanide, and one did not respond. Three were treated with long courses of vancomycin, but had persisting symptoms and signs of colitis until they died. Thus, in total, 23 of 35 (66%) patients with C. difficile colitis recalcitrant to standard therapies were eventually cured by nitazoxanide. 24, 26, 27 (see Figure 3) . Eight (62%) isolates were PFGE type NAP-2, toxinotype 0 and binary toxin negative. The remaining three (23%) isolates were of as-yet unnamed PFGE types.
Discussion
Nosocomial C. difficile colitis has evolved into a major problem in developed countries. 1 -4,24,26 Recent studies 3, 4, 12 indicate that as many as 20-25% of patients with this condition fail therapy with metronidazole, and another 20 -25% have recurrent disease, substantially higher rates of failure than were previously reported. 7 The usual therapy for patients who fail metronidazole has been oral vancomycin, but there is great reluctance to prescribe this drug because of concern for selection of vancomycinresistant bacteria. 15 Nitazoxanide has recently been shown to be at least as effective as metronidazole in the initial treatment of moderately severe to severe C. difficile colitis. Taken together, these factors motivated us to study nitazoxanide in treating patients who fail conventional therapy for this infection.
We identified 35 patients in whom C. difficile colitis had plainly failed treatment with metronidazole; 28 of these had persistent symptoms of colitis despite prolonged therapy with Figure 3 . PFGE of C. difficile isolated from 13 patients in this study. The figure shows that no single strain predominated. Eight of 13 isolates were NAP-2, toxinotype 0, and binary toxin negative, representing several different subtypes within PFGE NAP-2. Only two isolates were identified as the newly emerging NAP-1, toxinotype III, binary toxin positive epidemic strain. metronidazole, and seven had at least two relapses within a few weeks of an apparent response. A prompt response to nitazoxanide was seen in 26 (74%) cases, including 20 of the 28 (71%) who had persisting colitis despite metronidazole and six of the seven (86%) who had recurrent disease.
Of the 26 who responded to nitazoxanide, seven had recurrent C. difficile colitis, one of whom eventually responded to nitazoxanide. Of nine whose symptoms persisted during initial treatment with nitazoxanide, three were eventually cured by repeated course(s) of this drug. Thus, in aggregate, nitazoxanide produced a cure in 23 of 35 (66%) patients who had already failed other therapy, a response rate similar to that observed in initial treatment of unselected C. difficile colitis hospitalized patients with metronidazole. 3, 4 Achieving this rate of response in ill patients who had already failed prior therapy indicates a potentially important role for nitazoxanide in treating this disease.
PFGE showed that the majority of the strains studied were types other than the recently described NAP-1, toxinotype III, binary toxin positive isolate epidemic strain. 24 This finding indicates that the new, epidemic strain is not solely responsible for the recent increase in incidence and severity of C. difficile colitis in hospitalized patients in the USA. In our patients, the high failure rate appears to be more closely related to host factors, reflecting a population that is older and sicker than in the past, and that has received more broad coverage antibiotic therapy. More widespread usage of proton pump inhibitors may also play a contributory role. 28 Co-morbidities were prominent in our patients, and seven (20%) died within the 60 day study period. Further support for the central role of the host response in recurrent disease comes from our preliminary observation 29 that most of our patients had low levels of antibody to toxins A and B both acutely and in follow-up, a finding that is consistent with susceptibility to recurrent disease. 30 Antimicrobial resistance of C. difficile did not contribute to failure, because isolates from our patients were all susceptible to metronidazole, vancomycin, nitazoxanide and its metabolic product tizoxanide.
The chief limitation of this study is that, although prospective, it was open and non-comparative. At the time it was undertaken, there were precious few possible treatments, as emphasized by Louie 23 in his recent editorial. It is always possible that these patients might readily have responded to an additional course of conventional therapy. D. Gerding has shown (unpublished, presented at Symposium on Clostridium difficile, Annual Meeting Infectious Disease Society of America, 12 -15 October 2006) that some patients respond to metronidazole more slowly than was previously thought, and Pepin et al. 22 have reported that metronidazole may bring about a response in one-third of patients who are re-treated for a recurrence following therapy with that drug. That is why our inclusion criteria were so stringent. Patients who failed metronidazole had been treated for at least 14 days (mean duration of treatment was 22.4 days), and those with recurrent disease all had at least two recurrences (mean number of recurrences, 2.6).
We have reviewed elsewhere 6,31 the use of other therapeutic modalities for C. difficile colitis, including biological agents such as non-toxigenic C. difficile or other non-toxigenic bowel flora, antimicrobial agents such as bacitracin, teicoplanin and rifaximin, 32 toxin-binding polymers, 33 immune globulin 34, 35 or monoclonal antibody to C. difficile toxin, 36 and non-steroidal anti-inflammatory drugs. As always, prevention is better than treatment, and continued emphasis on judicious use of antibiotics and appropriate infection control measures remain central to the art of good medical practice.
